Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



RLS for RLS: Resources, Learnings, and Strategies for Improving Outcomes in Restless Legs Syndrome

neuroscienceCME Journal Club

Premiere Date: Wednesday, July 10, 2013

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date:
Thursday, July 10, 2014

presurvey

Faculty


W. Vaughn McCall, MD, MSW. Vaughn McCall, MD, MS (Moderator)
Case Distinguished Chair
Department of Psychiatry and Health Behavior
Medical College of Georgia/Georgia Regents University
Augusta, GA

William G. Ondo, MDWilliam G. Ondo, MD (Faculty)
Professor of Neurology
University of Texas Health Science Center at Houston
Houston, TX

Statement of Need

When appropriately treated, patients with restless legs syndrome (RLS) can experience good benefits of therapy, leading to improved quality of life. However, evidence suggests that RLS remains underdiagnosed and undertreated in routine clinical practice. Undertreatment of RLS has negative effects on sleep and daytime activities; these can affect personal, family, and occupational life. Ongoing education is warranted to improve evidence-based and appropriate treatment of RLS. New practice guidelines are available; nonetheless, ongoing clinical challenges exist regarding the selection and optimization of treatment. In addition, patients require counseling when starting dopamine agonists, and clinicians may not be prepared to provide this support.

This neuroscienceCME Journal Club activity features expert faculty discussing a recent, peer-reviewed meta-analysis of RLS pharmacotherapy options. Using the featured article as a springboard for comparison, learners will explore the efficacy and safety of drug therapy for RLS and optimal selection of therapy as outlined in the recently updated 2012 guidelines on RLS from the American Academy of Sleep Medicine.


Featured Article: Wilt TJ, Macdonald R, Ouellette J, et al. Treatment for Restless Legs Syndrome. Comparative Effectiveness Review No. 86. AHRQ Publication No. 12(13)-EHC147-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2012. http://www.effectivehealthcare.ahrq.gov/ehc/products/334/1328/ CER86_RestlessLegsSyndrome_ExecutiveSummary_20121119.pdf.
View Full Article

Activity Goal

Make One Change Statement: To implement evidence-based diagnostic and treatment strategies for patients with RLS that are in accordance with 2012 updated guidelines from the American Academy of Sleep Medicine.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Explain the health-related quality of life effects of restless legs syndrome and its associated comorbidities.
  • Plan and implement evidence-based treatment regimens for patients with restless legs syndrome that are in accordance with updated, 2012 guidelines from the American Academy of Sleep Medicine.

The following learning objectives pertain only to those requesting CNE credit:

  • Explain the health-related quality of life effects of restless legs syndrome and its associated comorbidities.
  • Identify characteristics that can be used to differentiate restless legs syndrome from other diagnoses.
  • Describe the expected benefits of and potential risks associated with evidence-based therapies for restless legs syndrome.

Target Audience

Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals with an interest in restless legs syndrome

Financial Support

Supported by an educational grant from UCB, Inc.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hour (0.1 CEU)
Universal Activity Number: 0376-0000-13-008-L01-P (live programs)
0376-0000-13-008-H01-P (recorded programs)
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations must be completed online at www.neurosciencecme.com/TST793 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. McCall has disclosed that he is a consultant to Luitpold Pharmaceuticals, Inc.

Dr. Ondo has disclosed that he receives grant support from Dystonia Coalition; Ipsen Biopharmaceuticals, Inc.; US WorldMeds; and Tremor Research Group. He is on the speakers bureau of Ipsen Biopharmaceuticals, Inc.; Lundbeck; Merz Pharma; Teva Pharmaceutical Industries LTD; UCB, Inc.

Howard Bliwise, MD (peer reviewer) has no disclosures to report

Ruth Cody, BSN, RN-BC (Peer Reviewer) has no disclosures to report.

Monique Johnson, MD, CCMEP (planning committee) has no disclosures to report.

Catherine F. Murray (planning committee) has no disclosures to report.

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and UCB, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

JC-017-071013-39

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download